版本:
中国

BRIEF-Roche's O'Day says has seen no more thromboembolic events with ACE910

April 27 Roche

* Drugs head Dan O'Day says access limitations for multiple sclerosis medicine Ocrevus in United States 'are really none'

* Says he is hopeful ACE910 will be available to hemophilia patients by end of 2017, early 2018

* O'Day says has seen no more significant thromboembolic events with ACE910 beyond those already reported

* Says Lucentis sales seen rising in FY2017, though pace may slow from 9 percent in first quarter Source text for Eikon: Further company coverage: (Reporting by John Miller)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐